Vigmed initiates the process of listing on NASDAQ OMX Small Cap
The Board of Vigmed Holding AB conducted on August 19 its annual strategic review. At this meeting, the Board, as a consequence of a now expanded ambition, decided to form an operating company in China as a subsidiary of Vigmed China Ltd. in Hong Kong. Through the newly formed company Vigmed plans to initiate a registration process of selected products on the Chinese market. The Company intends to communicate an action plan for the Asian market during the autumn.
Furthermore, it was decided to initiate a process to prepare the company for a change of venue for the company's shares from NASDAQ OMX First North to NASDAQ OMX Stockholm Small Cap. This is seen as a natural step considering the anticipated growth linked to the fact that the company now has started selling its products in selected markets and gradually intends to launch new product lines as well as enter a number of additional markets. Additionally, an increased interest among institutional investors, equity analysts and partners is anticipated.
Finn Ketler, CEO, comments, "These decisions are the natural result of the company's expected rapid expansion. After a challenging period securing the product quality and stabilizing production, we are entering a very exciting and positive commercialization phase. With a very competent and motivated organization in place and through the cooperation with our partners and end customers, we are now actively through our products working towards reducing risks of disease transmission through needle products”.
For further information contact:
Chairman of the board, Lennart Holm +46 70-630 8562 or CEO, Finn Ketler +46 42 600 5311
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20 employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the Company’s Certified Advisor.
Additional information such as company description, a video presentation and risk factors can be found on Vigmed’s website: www.vigmed.com/investor